This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 Nov 2010

Roche dumps hep C development deal with Ligand

Roche is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals, according to the UK biotech.

Roche is dumping another development pact. This time the Swiss pharma giant is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals ($LGNDD), according to the UK biotech.

The two companies struck a deal back in 2008 to use Metabasis' liver-targeting technology to find a new approach to treating the viral disease. Reuters reports that Ligand filed regulatory paperwork indicating that Roche's termination includes its commitment not to develop similar compounds in the next 10 years.

There's no word from either company what prompted the move, but Roche has launched a wide-ranging restructuring that recently spurred the company to write off $500 million in R&D work regarding RNAi programs.

Ligand says it first heard of Roche's decision on Friday. The developer earned a $6.5 million milestone from Roche last spring after the pharma company pushed RG7348 into Phase I. Ligand acquired its technology partner Metabasis at the beginning o

Related News